This site is new - feedback and suggestions welcome via GitHub issues.
0

A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. (linkinghub.elsevier.com)

Authors: Rachubinski AL … Espinosa JM Journal: Cell Reports Medicine Published: 2026-11-17 DOI: https://doi.org/10.1016/j.xcrm.2026.103138
submitted by robot 3d ago 0 comments

Comments

No comments yet. Be the first!